Implementation of HaemScreen, a workplace-based genetic screening program for hemochromatosis

Clinical Genetics

Volumn 65, Issue 5, 2004, Pages 358-367

  Nisselle, A E ^a   Delatycki, Martin B ^a   Collins, V ^a   Metcalfe, S ^a,b   Aitken, M A ^a,b   du Sart, D ^a   Halliday, J ^a   Macciocca, I ^a   Wakefield, A ^a   Hill, V ^a   Gason, A ^a,b   Warner, B ^a   Calabro, V ^a   Williamson, R ^a,b   Allen, K J ^a,c  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b Department of Civil and Environmental Engineering   (Australia)

^c ROYAL CHILDREN'S HOSPITAL   (Australia)

Author keywords

C282Y; Education; Genetic screening; Hemochromatosis; Implementation; Workplace

Indexed keywords

DNA; HFE PROTEIN;

ADVERTIZING; ARTICLE; ATTITUDE; CHEEK MUCOSA; CONTROLLED STUDY; DECISION MAKING; DNA DETERMINATION; EDUCATION PROGRAM; FEMALE; FOLLOW UP; GENE MUTATION; GENETIC ANALYSIS; GENETIC SCREENING; HEALTH PROGRAM; HEMOCHROMATOSIS; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; IRON OVERLOAD; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; MEDICAL INFORMATION; OUTCOMES RESEARCH; PATHOGENESIS; PENETRANCE; PILOT STUDY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; VIDEOTAPE; WORKPLACE;

ADOLESCENT; ADULT; ADVERTISING; ATTITUDE TO HEALTH; AUSTRALIA; FEMALE; GENETIC SCREENING; HEMOCHROMATOSIS; HUMANS; MALE; MIDDLE AGED; PATIENT EDUCATION; POINT MUTATION; WORKPLACE;

EID: 2442715056     PISSN: 00099163     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1399-0004.2004.0239.x     Document Type: Article

References (42)

1. Powell LW, Subramaniam VN, Yapp TR. Hemochromatosis in the new millennium. J Hepatol 2000: 32: 48-62.
2. Feder JN, Gnirke A, Thomas W et al. A novel MHC class I-like gene is mutated in patients with hereditary hemochromatosis. Nat Genet 1996: 13 (4): 399-408.
3. Jazwinska EC, Cullen LM, Busfield F et al. Hemochromatosis and HLA-H. Nat Genet 1996: 14 (3): 249-251.
4. Olynyk JK, Cullen DJ, Aquilia S et al. A population-based study of the clinical expression of the hemochromatosis gene. N Engl J Med 1999: 341: 718-724.
5. Beutler E, Felitti VJ, Koziol JA et al. Penetrance of 845G → A (C282Y) HFE hereditary hemochromatosis mutation in the USA. Lancet 2002: 359: 211-218.
6. Allen KJ, Warner B, Delatycki MB. Clinical hemochromatosis in HFE mutation carriers. Lancet 2002: 360: 412-413.
7. Cox T, Rochette J, Camaschella C et al. Clinical hemochromatosis in HFE mutation carriers. Lancet 2002: 360: 412.
8. Poullis A, Moodie SJ, Maxwell JD. Clinical hemochromatosis in HFE mutation carriers. Lancet 2002: 360: 411-412.
9. Bulaj ZJ, Ajioka RS, Phillips JD et al. Disease-related conditions in relatives of patients with hemochromatosis. N Engl J Med 2000: 343: 1529-1535.
10. Deugnier Y, Jouanolle AM, Chaperon J et al. Gender-specific phenotypic expression and screening strategies in C282Y-linked hemochromatosis: a study of 9396 French people. Br J Haematol 2002: 118: 1170-1178.
11. Ajioka RS, Kushner JP. Clinical consequences of iron overload in hemochromatosis homozygotes. Blood 2003: 101: 3351-3353.
12. Beutler E. The HFE Cys282Tyr mutation as a necessary but not sufficient cause of clinical hereditary hemochromatosis. Blood 2003: 101: 3347-3350.
13. Niederau C, Fischer R, Purschel A et al. Long-term survival in patients with hereditary hemochromatosis. Gastroenterology 1996: 110: 1107-1119.
14. Wilson J, Junger G. The principles and practice of screening for disease. Public Health Paper 34, Geneva: World Health Organization, 1968.
15. Ware JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992: 30: 473-483.
16. Spielberger C, Gorusch R, Luchene R. State Trait Anxiety Inventory: Manual. Palo Alto: Consulting Psychologists Press, 1983.
17. Marteau TM, Bekker H. The development of a six-item short-form of the state scale of the Spielberger State-Trait Anxiety Inventory (STAI). Br J Clin Psychol 1992: 31: 301-306.
18. Delatycki M, Allen K, Williamson R. Insurance agreement to facilitate genetic testing. Lancet 2002: 359: 1433.
19. Watson EK, Mayall E, Chapple J et al. Screening for carriers of cystic fibrosis through primary health care services. BMJ 1991: 303: 504-507.
20. Schenck U, von Karsa L. Cervical cancer screening in Germany. Eur J Cancer 2000: 36: 2221-2226.
21. Rudiman R, Gilbert FJ, Ritchie LD. Comparison of uptake of breast screening, cervical screening, and childhood immunisation. BMJ 1995: 310: 229.
22. Strecher V, Rosenstock I. The health belief model. In: Glanz K, ed. Health Behaviour and Health Education. San Francisco: Jossey-Bass Inc., 1997.
23. Gason A, Sheffield E, Bankier A et al. Evaluation of a Tay-Sachs disease screening program. Clin Genet 2003: 63: 386-392.
24. Foster P, Anderson CM. Reaching targets in the national cervical screening programme: are current practices unethical? J Med Ethics 1998: 24: 151-157.
25. Ward J. Population-based mammographic screening: does 'informed choice' require any less than full disclosure to individuals of benefits, harms, limitations and consequences? Aust N Z J Public Health 1999: 23: 301-304.
26. Slaytor EK, Ward JE. How risks of breast cancer and benefits of screening are communicated to women: analysis of 58 pamphlets. BMJ 1998: 317: 263-264.
27. Slater DN. Are women sufficiently well informed to provide valid consent for the cervical smear test? Cytopathology 2000: 11: 166-170.
28. Alderman MH, Lamport B. Treatment of hypertension at the workplace: an opportunity to link service and research. Health Psychol 1988: 7: 283-295.
29. Fitzgerald ST, Gibbens S, Agnew J. Evaluation of referral completion after a workplace cholesterol screening program. Am J Prev Med 1991: 7: 335-340.
30. Stave GM, Mignogna JJ, Powell GS et al. Evaluation of a workplace hemochromatosis screening program. Am J Prev Med 1999: 16: 303-306.
31. Barton JC, Cheatwood SM, Key TJ et al. Hemochromatosis detection in a health screening program at an Alabama forest products mill. J Occup Environ Med 2002: 44: 745-751.
32. Cogswell ME, McDonnell SM, Khoury MJ et al. Iron Overload, Public Health, and Genetics: Evaluating the evidence for hemochromatosis screening. Ann Intern Med 1998: 129: 971-979.
33. Davis JG. Population screening for hemochromatosis: the evolving role of genetic analysis. Ann Intern Med 1998: 129: 905-908.
34. Burt MJ, George PM, Upton JD et al. The significance of hemochromatosis gene mutations in the general population: implications for screening. Gut 1998: 43: 830-836.
35. Burke W, Thomson E, Khoury MJ et al. Hereditary hemochromatosis: gene discovery and its implications for population-based screening. JAMA 1998: 280: 172-178.
36. Haddow JE, Bradley LA. Hereditary hemochromatosis: to screen or not. Conditions for screening are not yet fulfilled. BMJ 1999: 319: 531-532.
37. Allen K, Williamson R. Screening for hereditary hemochromatosis should be implemented now. BMJ 2000: 320: 183-184.
38. Adams PC. Population screening for hemochromatosis. Gut 2000: 46: 301-303.
39. Gertig D, Hopper J, Allen K. Population genetic screening for hereditary hemochromatosis. Med J Aust 2003: 179 (10): 517-518.
40. Keays D. The legal implications of genetic testing: insurance, employment and privacy. J Law Med 1999: 6: 357-372.
41. Rowley PT, Loader S, Sutera CJ et al. Prenatal screening for hemoglobinopathies. I. A prospective regional trial. Am J Hum Genet 1991: 48: 439-446.
42. Collins FS, Green ED, Guttmacher AE et al. A vision for the future of genomics research. Nature 2003: 422: 835-847.